The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesFACS: Use 10µl for 106 cells in 100µl.
WB: Use at an assay dependent dilution. Predicted molecular weight: 19 kDa.
Is unsuitable for ELISA.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionProduced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
Tissue specificityReleased primarily from activated T lymphocytes.
Involvement in diseaseIn Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.
Sequence similaritiesBelongs to the type II (or gamma) interferon family.
Post-translational modificationsProteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161.
References for Anti-Interferon gamma antibody [7B6] (ab27919)
This product has been referenced in:
Weynants V et al. Quantitative assessment by flow cytometry of T-lymphocytes producing antigen-specific gamma-interferon in Brucella immune cattle. Vet Immunol Immunopathol66:309-20 (1998).
Read more (PubMed: 9880107) »